Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Use of epoetin in chronic renal failure.

Coyne DW.

JAMA. 2007 Apr 18;297(15):1713-6. No abstract available.

PMID:
17440149
[PubMed - indexed for MEDLINE]
2.

Epoetin dosing and dialysis facility ownership.

Kliger AS, Nissenson AR.

JAMA. 2007 Aug 22;298(8):861-2; author reply 862-3. No abstract available.

PMID:
17712067
[PubMed - indexed for MEDLINE]
3.

Epoetin dosing and dialysis facility ownership.

Regidor DL, Kalantar-Zadeh K, Kovesdy CP.

JAMA. 2007 Aug 22;298(8):862; author reply 862-3. No abstract available.

PMID:
17712068
[PubMed - indexed for MEDLINE]
4.

Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.

Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernán MA.

JAMA. 2007 Apr 18;297(15):1667-74.

PMID:
17440144
[PubMed - indexed for MEDLINE]
5.

Effects of Epoetin alfa on hemostasis in chronic renal failure.

Tang WW, Stead RA, Goodkin DA.

Am J Nephrol. 1998;18(4):263-73. Review.

PMID:
9653828
[PubMed - indexed for MEDLINE]
6.

Oxidative stress in renal anemia of hemodialysis patients is mitigated by epoetin treatment.

Siems W, Carluccio F, Radenkovic S, Grune T, Hampl H.

Kidney Blood Press Res. 2005;28(5-6):295-301. Epub 2006 Mar 7.

PMID:
16534224
[PubMed - indexed for MEDLINE]
7.

Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.

Więcek A, Ahmed I, Scigalla P, Koytchev R.

Adv Ther. 2010 Dec;27(12):941-52. doi: 10.1007/s12325-010-0080-z. Epub 2010 Oct 22.

PMID:
20972656
[PubMed - indexed for MEDLINE]
8.

Anemia management in dialysis: Why the FDA and CMS have it right (and how KDIGO got it wrong).

Coyne DW.

Nephrol News Issues. 2013 Feb;27(2):16, 18, 20. No abstract available.

PMID:
23469454
[PubMed - indexed for MEDLINE]
9.

Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.

Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U; Ba16285 Study Investigators.

Clin Ther. 2007 Apr;29(4):626-39.

PMID:
17617286
[PubMed - indexed for MEDLINE]
10.

Finding a rational approach to ESA therapy--for payers and patients.

Messana A.

Nephrol News Issues. 2007 Sep;21(10):54, 56. No abstract available.

PMID:
17918481
[PubMed - indexed for MEDLINE]
11.

Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.

Binkley LS.

Transplant Proc. 1991 Apr;23(2):1831-2. Review. No abstract available.

PMID:
2053169
[PubMed - indexed for MEDLINE]
12.

Selected research topics.

[No authors listed]

Am J Kidney Dis. 1991 Nov;18(5 Suppl 2):96-104. No abstract available.

PMID:
1951363
[PubMed - indexed for MEDLINE]
13.

[Current issues in erythropoietin therapy of renal anemia].

Zakar G.

Lege Artis Med. 2007 Oct;17(10):667-73. Review. Hungarian.

PMID:
19227596
[PubMed - indexed for MEDLINE]
14.

Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.

Collins AJ, Monda KL, Molony JT, Li S, Gilbertson DT, Bradbury BD.

Am J Kidney Dis. 2014 Jun;63(6):997-1006. doi: 10.1053/j.ajkd.2013.10.052. Epub 2013 Dec 4.

PMID:
24315770
[PubMed - indexed for MEDLINE]
15.

A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries.

Leese B, Hutton J, Maynard A.

Pharmacoeconomics. 1992 May;1(5):346-56.

PMID:
10146999
[PubMed - indexed for MEDLINE]
16.

Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.

Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R; Epoetin Zeta Study Group.

Curr Med Res Opin. 2008 Mar;24(3):625-37. doi: 10.1185/030079908X273264. Erratum in: Curr Med Res Opin. 2008 Oct;24(10):3007. Curr Med Res Opin. 2008 Apr;24(4):1155.

PMID:
18208642
[PubMed - indexed for MEDLINE]
17.

Darbepoetin alpha is highly cost-effective compared with epoetin alpha in the treatment of renal anemia: a brief report from a hemodialysis clinic in Japan.

Nakagawa T.

Ther Apher Dial. 2008 Dec;12(6):531-2. doi: 10.1111/j.1744-9987.2008.00644.x. No abstract available.

PMID:
19140854
[PubMed - indexed for MEDLINE]
18.

The KDIGO anemia guideline: can reason triumph over regulation?

Wish JB.

Nephrol News Issues. 2012 Dec;26(13):20, 22-3. No abstract available.

PMID:
23346853
[PubMed - indexed for MEDLINE]
19.

Epoetin bubble: a severe German case Honi soit qui mal y pense.

Wizemann V.

Nephrol Dial Transplant. 2011 May;26(5):1750-2; author reply 1752. doi: 10.1093/ndt/gfr016. Epub 2011 Mar 4. No abstract available.

PMID:
21378149
[PubMed - indexed for MEDLINE]
Free Article
20.

Understanding epoetin use: databases or clinical trials?

Roger SD.

Nephrology (Carlton). 2007 Apr;12(2):118-9. No abstract available.

PMID:
17371331
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk